



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	10/506729	
			Filing Date	September 3, 2004	
			First Named Inventor	Andrew Stocker	
			Art Unit	4615-1626	
			Examiner Name	Not Yet Assigned M. BARKER	
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-664

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MB	AA	US-2004/0002495-A1	01-01-2004	Philip Sher	
MB	AB	US-3,706,810	12-19-1972	<del>AMERICAN CYANAMIDE</del> <i>Drabander et al.</i>	
MB	AC	US-4,599,198	07-08-1986	DENNIS J. HOOVER	
MB	AD	US-4,668,769	05-26-1987	DENNIS J. HOOVER	
MB	AE	US-4,720,503	01-19-1988	BRUCE E. WITZEL	
MB	AF	US-4,751,231	06-14-1988	WASYL HALCZENKO	
MB	AG	US-4,786,641	11-22-1988	SIEGFRIED GOLDMANN	
MB	AH	US-4,794,120	12-27-1988	PHILIPPE MANOURY	
MB	AI	US-5,863,903	01-26-1999	KARSTEN LUNDGREN	
MB	AJ	US-5,998,463	12-07-1999	BERNARD HULIN	

*BF*  
*10/6/06*

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code* -Number* -Kind Code* (if known)				
MB	BA	WO-00/42213		07-20-2000	The Research Foundation of State University of New York	
MB	BB	WO-00/47206		08-17-2000	Novo Nordisk	
MB	BC	WO-01/05954		01-25-2001	Isis Pharmaceuticals, Inc.	
MB	BD	WO-01/23347		04-05-2001	Novo Nordisk	
MB	BE	WO-01/32654		05-10-2001	Societe de Conseils de Recherches et D'Applications Scientifiques	
MB	BF	WO-01/52825		07-26-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	
MB	BG	WO-01/68055		09-20-2001	Pfizer Products Inc.	
MB	BH	WO-01/68092		09-20-2001	Pfizer Products Inc.	
MB	BI	WO-01/68603		09-20-2001	Bristol-Myers Squibb Co.	
MB	BJ	WO-01/94300		12-13-2001	Aventis Pharma Deutschland	
MB	BK	WO-01/96311		12-20-2001	Bristol-Myers Squibb Company	
MB	BL	WO-01/96347		12-20-2001	Bristol-Myers Squibb Company	
MB	BM	WO-02/080844		10-17-2002	Genzyme Corporation	
MB	BN	WO-02/096864		12-05-2002	Aventis Pharma Deutschland GmbH	
MB	BO	WO-02/098348		12-12-2002	Eli Lilly and Company	
MB	BP	WO-02/26714		04-04-2002	Takeda Chemical Industries, Ltd.	
MB	BQ	WO-02/34718		05-02-2002	Richter Gedeon Vegyeszeti Gyar Rt.	
MB	BR	WO-03/037864		05-08-2003	Japan Tobacco Inc.	
MB	BS	EP-0846464		06-10-1998	Pfizer Inc.	
MB	BT	EP-0884050		12-16-1998	Novo Nordisk	
MB	BU	EP-0978279		02-09-2000	Pfizer Products Inc.	
MB	BV	EP-1088824		01-07-2004	Pfizer Products Inc.	
MB	BW	EP-1125580		08-22-2001	Pfizer Products Inc.	
MB	BX	EP-1134213		09-19-2001	Pfizer Inc.	
MB	BY	EP-1136071		09-26-2001	Pfizer Products Inc.	
Examiner Signature <i>M. P. B.</i>				Date Considered	3-15-06	